Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at Michigan Medicine have developed a nanoparticle-based treatment that targets cancer cells, increasing therapeutic response and reducing drug toxicity. The treatment uses dendrimers to deliver methotrexate and folate, allowing the cancer cells to internalize the drugs while minimizing harm to normal cells.
A novel technique developed by Stanford researchers allows scientists to distinguish between possible cancer-causing genes and those that are harmless. Mutations in the PI3K gene were found to be a primary driver of melanoma, while a mutation in the B-Raf gene did not cause cancer despite being commonly associated with the disease.
A 14-month study found that dexmethyphenidate (d-MPH) significantly reduced fatigue and improved memory in cancer survivors with chemobrain. The medication, taken at dosages of 10-50 mg per day, showed safe and effective results for relieving chemobrain symptoms.
A recent analysis found that U.S. adults could save up to $8.8 billion per year by using generic drugs instead of brand-name drugs. Additionally, a study on Gulf War veterans revealed four more common health conditions among those who served in the conflict compared to non-deployed individuals.
A study found that a life-long deficiency of insulin-like growth factor-1 (IGF-1) decreased cancer risk by approximately 45 percent and decreased cancer deaths by 12-15 percent. Low-calorie diets may also reduce IGF-1 levels, potentially reducing cancer risk.
Researchers are exploring marine natural products as a source of new medicines, including compounds that target cancer cells and regulate calcium flow. One compound, phorboxazole, has shown potential in inhibiting tumor cell growth at low concentrations.
A study published in PNAS found that prenatal exposure to diethylstilbestrol (DES) can permanently alter tissue in rats, making them more susceptible to hormone-dependent tumors. The researchers believe this phenomenon could explain why some people with inherited tumor suppressor gene defects develop cancer while others do not.
A new study found that long-term daily use of aspirin was associated with an increased risk of ER/PR-negative breast cancer, while long-term daily use of ibuprofen was linked to a higher risk of nonlocalized breast cancer. Regular NSAID use was not associated with breast cancer risk.
A new study found that statin use can decrease the risk of colon cancer in people taking cholesterol-lowering medications. Researchers analyzed data from over 1,900 participants and found a 47% reduced risk of colorectal cancer among those taking statins.
Pediatric oncologist Peter C. Adamson emphasizes the need for targeted treatments that spare healthy cells, reducing toxic side effects. The Institute of Medicine report proposes a public-private partnership to develop new pediatric anticancer drugs.
Scientists at UCSB have discovered a protein called vacuolar ATPase that naturally prevents inappropriate cell fusion, which can lead to cancer metastasis. This finding may pave the way for new treatments to enhance organ regeneration by stem cells, prevent cancer progression, and control fertility.
A new polysaccharide, hyaluronan oligomers, has been discovered to sensitize drug-resistant breast cancer cells to several chemotherapeutic drugs by binding to CD44 receptor. Increasing hyaluronan synthesis in cells also increases resistance to drug treatment.
Researchers found that dutasteride suppresses blood flow in benign prostate tissue, enabling targeted biopsies to detect cancer more effectively. This reduction in benign blood flow improved cancer detection rates and may reduce the need for repeat biopsies.
Researchers at UNC Health Care System have developed a new continuous-infusion method for administering busulfan, which achieved more predictable levels of the drug in patients. The new method has the potential to increase treatment effectiveness while avoiding side effects by maintaining consistent drug levels.
A new protein targets tumor vasculature by inducing coagulation when administered systemically, delaying tumor growth and producing some tumor regressions. The treatment shows promise for cancer therapy, adding a powerful punch to the fight against cancer.
Researchers studied the combination of S-1, a new drug, and cisplatin in patients with advanced gastric cancer. Overall, 65% of patients responded to the chemotherapy, showing tumors shrunk in response to the drug.
Researchers found that most imaging scans are unnecessary and can be avoided by confirming medication delivery within 24 hours of indium 111-labeled Zevalin injection. This simplifies treatment and improves patient compliance.
A study found that cetuximab, an Erbitux-based treatment, helped shrink tumors and extend survival in patients with metastatic colorectal cancer who had previously failed treatment. The typical patient survived 6.6 months after treatment.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.
Researchers found that blocking the Odc gene with the drug DFMO prevents cancer development in laboratory models, including lymphoma. The study suggests that a similar approach might prevent or slow cancer development in other types of cancer.
Researchers have identified a chaperone protein called HSP90 as the key player in green tea's protective effects against cancer. By understanding this mechanism, scientists hope to develop more potent anti-cancer compounds.
A study by the University of California - Davis Health has demonstrated a significantly improved survival rate for locally advanced lung cancer patients using a chemotherapy regimen that includes docetaxel. The study showed a five-year survival rate of 29 percent, surpassing previous results.
Researchers discovered an antibody compound that effectively targets and destroys blood vessels within cancerous tumors, reducing tumor growth by 93% when combined with docetaxel. This promising treatment approach may offer a new solution to treating breast cancer patients with limited effectiveness from traditional therapies.
A phase II clinical trial evaluated SU11248 for carcinoid and pancreatic islet cell tumors, demonstrating 80% stabilization of disease progression. The drug hinders key proteins and receptors that cancer cells rely on to thrive.
Researchers found no improvement in hot flash symptoms when women took black cohosh compared to placebo. In contrast, a progestational agent reduced hot flashes by up to 90% and improved sleep quality, with benefits lasting at least six months.
A phase II trial found that Herceptin can be used safely for bladder cancer with few serious adverse effects related to the drug. The study showed good responses to treatment in patients with HER2-positive bladder cancer, laying the foundation for a future phase III trial.
A new kidney cancer drug has shown a partial response rate of 40% in patients with metastatic renal cell carcinoma, significantly higher than the standard treatment's 15% response rate. The medication, SU11248, was well-tolerated and had significant side effects, but offered improved survival rates for some patients.
Researchers at Vanderbilt University Medical Center found that adding bevacizumab to standard chemotherapy extended median survival by 2.3 months, improving overall tumor response rates and progression-free survival. This new treatment regimen is recommended as the standard for advanced non-small cell lung cancer patients.
Researchers have discovered a new way to selectively block estrogen's effects using the Tamoxifen-like drug GW5638. This breakthrough could lead to more effective treatments for breast cancer and other estrogen-related diseases without increasing the risk of endometrial cancer.
A Massey Cancer Center researcher has identified the atomic structure of angiopoietin-2, a key protein involved in the neo-vascularization of solid tumors. This discovery may lead to better exploration of how to turn off cancer growth signals and identify potential therapeutics.
A combination of chemotherapy drugs showed improved overall and progression-free survival rates compared to a single drug, gemcitabine. Patients treated with the combination regimen (PEGF) had a higher percentage alive without disease after 4 months than those on standard treatment.
Researchers found that advanced NSCLC patients with high EGFR gene copy number, protein expression, or mutations respond better to gefitinib. High EGFR gene copy number is associated with prolonged survival and disease control.
The Research on Adverse Drug Events and Reports (RADAR) Project has identified serious adverse drug reactions with 14 commonly prescribed drugs and cardiac stents, affecting almost 1,700 patients. RADAR reviews have been published in leading medical journals and have helped save hundreds to thousands of patient lives.
The FDA approved clofarabine for pediatric patients with relapsed or refractory ALL, built on years of effective use of pre-1980 drugs and adaptable for adult use later. Researchers say this approval is crucial for giving children access to new anti-cancer drugs.
A study by Vanderbilt University researchers found that inhibiting COX-1 slowed the growth of epithelial ovarian tumors in a mouse model. This breakthrough suggests targeting COX-1 as a novel approach to prevent and treat ovarian cancer.
A new study found that slow recovery of normal white blood cells and high levels of leukaemic cells are predictive of relapse. The researchers discovered that these two factors predict outcome by distinct mechanisms, offering potential for personalized therapy adjustment.
A study found that commercially available extracts of black cohosh increased cell killing by two of four drugs used in cancer therapy for breast cancer patients. However, the herb also decreased the effectiveness of one drug. Further research is needed to understand why these effects occur.
RAD001 targets mTOR enzyme in high-AKT activity ovarian cancer cells, arresting cell division and reducing angiogenesis. The treatment may be combined with chemotherapy to kill weakened cancer cells.
The HER-2 gene has been found to play a major role in prostate cancer recurrence, according to a new study published in Cancer Research. Inhibiting the HER-2 protein may provide a novel treatment strategy for targeting advanced prostate cancer.
Researchers have reported encouraging results with the novel drug AMN107, which is showing an increasingly strong benefit as doses are raised. Over 90% of patients with earlier stage Chronic Myeloid Leukemia (CML) have achieved a hematologic response, and over 70% of those in advanced stages have also benefited.
Research reveals that the compound damages DNA by targeting two enzymes: thymidylate synthase and topoisomerase. This understanding could enable combination therapies for greater effectiveness and better patient outcomes. The compound has been shown to be 300-400 times more effective than fluorouracil at killing cancer cells.
Scientists have developed a new compound, AMN107, that shows promise in overcoming resistance to Gleevec, a highly successful leukemia treatment. In studies, AMN107 was found to be at least 20 times more potent than Gleevec against most resistant mutants, offering a potential cure for patients with acquired drug resistance.
The study found that sulindac induced expression of the p21 gene, which suppressed tumor formation even in mice missing key tumor suppressor genes and fed a high-fat diet. The researchers suggest that p21 activation through sulindac offers protection against both genetic and dietary factors contributing to cancer development.
Penn researchers have determined the structure of Erbitux's binding site to cancer cells, providing new insight into how it blocks cell growth-promoting activities. This finding will steer future treatment design for colon-cancer medications and potentially lead to easier delivery methods.
A recent study published by Johns Hopkins Medicine suggests that statin use may lower the risk of developing advanced prostate cancer by half. The researchers tracked 34,438 male health professionals and found that those taking cholesterol-lowering drugs had a significantly reduced risk of advanced prostate cancers.
Happiness has been found to be related to the functioning of key body processes, including lower cortisol levels and healthier cardiovascular systems. Researchers also discovered a Chinese herbal medicine component that can inhibit cancer cell growth.
A low-dose blend of celecoxib and Lipitor significantly reduces invasive and non-invasive colon adenocarcinomas by 95% in laboratory animals. The combination targets different molecular pathways to prevent colon cancer development, suggesting a promising approach for maximizing anti-cancer efficacy while minimizing toxicity.
Researchers developed a test to measure CDK activity, which accurately predicts tumor response to Tarceva. A second study found that increased CDK activity correlates with sensitivity to Taxol, providing preclinical evidence for developing a novel device to measure CDK activity in human tissue.
Despite extensive education, few high-risk women consider taking tamoxifen to prevent breast cancer due to concerns over side effects and low perceived risk. Only a small percentage of eligible women would take the drug after learning about its benefits.
Researchers found that ephrin subtype EphrinB activates the EphB receptor, triggering a chemical pathway that stimulates synaptojanin-1 enzyme, essential for cellular endocytosis. This process is crucial for neurotransmitter regulation and nerve cell function.
Researchers found no detectable levels of SV40 in 69 tumors tested using a highly sensitive assay. The study's protocol aimed to eliminate possible contamination from DNA vectors used in laboratories worldwide.
The American Association for Cancer Research has conferred international awards to world-class scientists, with recipients presenting lectures at the AACR Annual Meeting. The honorees represent leading researchers in basic research, clinical care, and prevention.
Researchers have found a trio of proteins that protect tumor cells from destruction by radiotherapy, and a deeper understanding of their relationship could lead to more effective treatment. Genetic testing could help doctors identify the most effective treatment method for each patient's unique cancer tissue.
The AACR-Minorities in Cancer Research-Jane C. Wright Lectureship recognizes outstanding scientists advancing minority investigators in cancer research. Dr. Wright's pioneering work in clinical cancer chemotherapy and leadership in the field have a lasting impact on cancer research.
Cantley's discovery of phosphoinositide 3-kinase (PI3K) revealed a new lipid produced only when cells are stimulated with growth factors or made cancerous. His work has supported the model that PI3K plays a critical role in many human cancers, and its inhibition is being explored for various diseases.
The AACR Minority Scholar Awards program aims to increase minority participation in cancer research by providing opportunities for young scientists and clinicians. The program's 20th anniversary is being celebrated with a special session and gala, honoring past award recipients and recognizing the contributions of minority researchers.
Researchers found that combining chemotherapy with Herceptin before surgery in early-stage breast cancer patients resulted in a 42% higher tumor reduction and 66.7% pathological complete remission rate compared to chemotherapy alone. The combination also showed less risk of heart damage, leading the clinical trial to be halted early.
Dr. Waldemar Debinski has developed a novel treatment approach for glioblastoma, the most aggressive form of brain cancer, by targeting specific receptors on cancer cells. The therapy combines a form of interleukin-13 with a toxin that kills cancer cells without damaging healthy tissue.
Most cancer survivors can return to work after treatment, but a minority face ongoing problems requiring comprehensive support services. The study found that similar numbers of men and women stop working during treatment, with the lowest rates among those with certain types of cancer.
Researchers at Boston Children's Hospital found that high cholesterol levels accelerate prostate cancer growth by activating a cell-survival pathway. Cholesterol-lowering drugs like simvastatin may inhibit tumor growth by inhibiting this pathway.